[CAS NO. 20150-34-9] Ferrousbisglycinate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [20150-34-9]

Catalog

HY-130078

Brand

MCE

CAS

20150-34-9

DESCRIPTION [20150-34-9]

Overview

MDL	MFCD07780318
Molecular Weight	201.95
Molecular Formula	C4H6FeN2O4
SMILES	O=C1[O-][Fe+2]2([O-]C(CN2)=O)NC1

For research use only. We do not sell to patients.

Summary

Ferrous bisglycinate is an orally active iron fortificants and therapeutic iron supplements. Ferrous bisglycinate can be used for the research of iron deficiency anemia ^[1] ^[2] .

In Vitro

Ferrous bisglycinate (25-200 μM; 2 h) does not affect the Caco-2 cells viability ^[2] .
Ferrous bisglycinate (25 μM; 2 h) increases ferritin content in the Caco-2 cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	Caco-2 cells
Concentration:	0, 25, 50, 100, 200 μM
Incubation Time:	2 hours
Result:	Did not affect the viability of wild-type and divalent metal transporter 1 (DMT1) knockout Caco-2 cells.

Western Blot Analysis ^[2]

Cell Line:	Caco-2 cells
Concentration:	25 μM
Incubation Time:	2 hours
Result:	Increased ferritin content and decreased DMT1 expression levels significantly in the wild-type cells.

In Vivo

Ferrous bisglycinate (500 mg/kg iron; p.o.) exerts a protective effect on colitis in mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female C57BL/6 mice are induced colitis by dextran sodium sulfate (DSS) ^[3]
Dosage:	500 mg/kg iron
Administration:	P.o. (add to the diet) for 10 days
Result:	Had the best survival rates (100%). Caused the least body lost (9% body loss).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01160198	GlaxoSmithKline	Haematopoiesis	October 13, 2010	Phase 3
NCT03009578	Assiut University	Anemia	February 1, 2017	Phase 3
NCT04017598	University of British Columbia\|Helen Keller International\|NCHADS - Ministry of Health of Cambodia\|BC Children´s Hospital Research Institute\|The National Institute of Public Health Laboratory, Phnom Penh	Anemia, Iron Deficiency\|Anemia\|Intestinal Inflammation\|Inflammation\|Intestine; Complaints	December 10, 2019	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

0.1 M HCL : 2 mg/mL ( 9.90 mM ; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.9517 mL	24.7586 mL	49.5172 mL
5 mM	0.9903 mL	4.9517 mL	9.9034 mL
10 mM	---	---	---

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 2 mg/mL (9.90 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

* All of the co-solvents are available by MCE.

References

Synonyms

Iron, bis(glycinato-κN,κO)-

Iron, bis(glycinato)-

Iron, bis(glycinato-N,O)-

Bis(glycinato-κN,κO)iron

Iron preparation SE

Bis(glycinato)iron

Ferrochel

Fechel

Ferrous bisglycinate

Iron glycinate

Ferrous glycinate

B-Traxim 2C Fe

Iron bisglycinate

Iron(2+) glycinate